• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Human Herpesvirus 8 (HHV-8) Infections - Pipeline Review, H2 2012 Product Image

Human Herpesvirus 8 (HHV-8) Infections - Pipeline Review, H2 2012

  • Published: September 2012
  • 37 pages
  • Global Markets Direct

Human Herpesvirus 8 (HHV-8) Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Human Herpesvirus 8 (HHV-8) Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Human Herpesvirus 8 (HHV-8) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Herpesvirus 8 (HHV-8) Infections. Human Herpesvirus 8 (HHV-8) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Human Herpesvirus 8 READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Human Herpesvirus 8 (HHV-8) Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Human Herpesvirus 8 (HHV-8) Infections 7
Human Herpesvirus 8 (HHV-8) Infections Therapeutics under Development by Companies 9
Human Herpesvirus 8 (HHV-8) Infections Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Human Herpesvirus 8 (HHV-8) Infections Therapeutics – Products under Development by Companies 14
Human Herpesvirus 8 (HHV-8) Infections Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Human Herpesvirus 8 (HHV-8) Infections Therapeutics Development 16
Microbiotix, Inc. 16
Arisyn Therapeutics Inc. 17
Human Herpesvirus 8 (HHV-8) Infections – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
ATI-0607 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
sorafenib tosylate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Interference Ribonucleic Acids - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Liposomal Doxorubicin + Bevacizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
vincristine sulfate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MBX-400 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
vif1 Peptide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Human Herpesvirus 8 (HHV-8) Infections Therapeutics – Discontinued Products 34
Human Herpesvirus 8 (HHV-8) Infections Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Human Herpesvirus 8 (HHV-8) Infections, H2 2012 7
Products under Development for Human Herpesvirus 8 (HHV-8) Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Microbiotix, Inc., H2 2012 16
Arisyn Therapeutics Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Human Herpesvirus 8 (HHV-8) Infections Therapeutics – Discontinued Products 34
Human Herpesvirus 8 (HHV-8) Infections Therapeutics – Dormant Products 35

List of Figures
Number of Products under Development for Human Herpesvirus 8 (HHV-8) Infections, H2 2012 7
Products under Development for Human Herpesvirus 8 (HHV-8) Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos